(Bloomberg) -- GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a prescription drug on LinkedIn. A panel of leaders at the PMCPA, pharma’s ...

After more than a decade in the United States, nuclear physicist Liu Chang, whose research has been crucial in the journey to achieve fusion energy, has left Princeton University for a position at ...

"I turned my phone back on at the end of the day and I had like 42 missed calls," the 'Last Breath' actor recalled of when he knew he'd lost his job Amy Sussman/WireImage Simu Liu is available for ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

Breeze Liu has been a prominent advocate for victims. But even she struggled to scrub nonconsensual intimate images and videos of herself from the web. Breeze Liu’s online nightmare started with ...

And once our homicidal odd couple picks up a third wheel played by Lucy Liu, Old Guy starts to feel like a bygone era’s idea of a cool movie, the sort of thing Quentin Tarantino or Steven ...

GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.